Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Lykera Biomed S.A.
DescriptionHumanized mAb against S100 calcium binding protein A4 (S100A4)
Molecular Target S100 calcium binding protein A4 (S100A4)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today